Company Analysis Seres Therapeutics, Inc.
1. Summary
Advantages
- Price (0.7767 $) is less than fair price (1.08 $)
- The stock's return over the last year (-32.46%) is higher than the sector average (-43.68%).
- Current debt level 30.18% is below 100% and has decreased over 5 years from 33.84%.
- The company's current efficiency (ROE=253.53%) is higher than the sector average (ROE=9.39%)
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Seres Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -6.4% | -25.1% | -5.1% |
| 90 days | -15.1% | -45.3% | -0.1% |
| 1 year | -32.5% | -43.7% | 19.2% |
MCRB vs Sector: Seres Therapeutics, Inc. has outperformed the "Healthcare" sector by 11.22% over the past year.
MCRB vs Market: Seres Therapeutics, Inc. has significantly underperformed the market by -51.64% over the past year.
Stable price: MCRB is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MCRB with weekly volatility of -0.6242% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.7767 $) is lower than the fair price (1.08 $).
Price significantly below the fair price: The current price (0.7767 $) is 39% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-3.62) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (-3.62) is lower than that of the market as a whole (3.44).
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.29) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (1.29) is lower than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.7) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.7) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 7.57% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (7.57%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (253.53%) is higher than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (253.53%) is higher than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-31.71%) is lower than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (-31.71%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-50.24%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-50.24%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
